June 16, 2022
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
May 18, 2022
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
May 12, 2022
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
April 7, 2022
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
March 1, 2022
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
February 3, 2022
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
January 20, 2022
Xilio TherapeuticsĀ Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
January 6, 2022
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors